Integration of Remote Monitoring in the Management of Chronic Immunosuppressive Therapy
Launched by UNIVERSITY OF PERUGIA · Aug 6, 2024
Trial Information
Current as of November 14, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how adding remote monitoring and support services can improve the management of chronic autoimmune diseases like rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, and others. These conditions often require long-term treatment with medications that suppress the immune system, helping to control symptoms and prevent complications. The researchers want to see if using technology to check in with patients more frequently, especially right after starting a new medication, leads to better adherence to treatment, improves patients' responses to their medications, and enhances their overall quality of life.
To be eligible for this study, participants must have one of the specified conditions and be prescribed a new immunosuppressive medication, such as methotrexate or TNF inhibitors. The trial is currently recruiting patients of all ages and genders. Participants can expect to have regular remote check-ins along with their usual doctor visits, which may help them feel more supported during their treatment journey. It’s important to note that individuals who cannot use remote communication devices, even with help, will not be able to participate.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Any patient with one of the following conditions
- • Rheumatoid Arthritis
- • Psoriatic Arthritis
- • Spondyloarthritis
- • Ankylosing Spondylitis
- • Systemic Sclerosis
- • Systemic Lupus Erythematosus
- * Sjogren's Disease who are prescribed a new immunosuppressive medication for the treatment of their disease among the following:
- • Methotrexate
- • Sulfasalazine
- • Leflunomide
- • Mycophenolate Mofetil
- • Azathioprine
- • Cyclosporine A
- • Tacrolimus
- • TNF inhibitors (etanercept, adalimumab, golimumab, certolizumab pegol)
- • IL6 inhibitors (tocilizumab)
- • IL-17 inhibitors (secukinumab, ixekizumab)
- • IL-23 inhibitors (ustekinumab, guselkumab, risankizumab)
- • JAK-inhibitors (tofacitinib, baricitinib, upadacitinib, filgotinib)
- • Belimumab
- • Anifrolumab
- Exclusion Criteria:
- • Treatment with a medication not approved for the condition
- • Inability to use a device for remote call, not even with the help of a caregiver
About University Of Perugia
The University of Perugia, a prestigious academic institution located in Italy, is dedicated to advancing medical research and clinical innovation through its robust clinical trial initiatives. With a strong emphasis on interdisciplinary collaboration and ethical standards, the university aims to contribute to the development of novel therapeutic strategies and improve patient outcomes. Leveraging its extensive network of healthcare professionals and cutting-edge facilities, the University of Perugia fosters a dynamic research environment that supports both local and international clinical studies, ultimately enhancing the quality of healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Perugia, Pg, Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported